Internal Medicine, Pulmonary Disease · Gaithersburg, MD
NPI
1447254230
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
16220 Frederick Rd, Ste 213
Gaithersburg, MD, 20877
Phone (301) 963-2770
Groups this clinician bills Medicare through
Medicare paid, 2024
$350K
4,616 services
Medicare patients, 2024
1,436
Average age 77
Drug cost, 2024
$3.4M
4,962 prescriptions
Company payments, 2025
$4,556
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joseph A Ball was code 99213 (office e&m - established), 1,258 times for 852 patients. In total Joseph A Ball billed 4,616 services in 31 codes, and Medicare paid $350K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-11-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 1,258 | 852 | $70.65 | $89K |
| 99214 Office E&M - Established | Office | 684 | 476 | $103.73 | $71K |
| 94010 Pulmonary Function Testing | Office | 359 | 337 | $24.18 | $8,680 |
| 99233 Hospital E&M - Subsequent | Facility | 326 | 134 | $94.93 | $31K |
| 71046 X-ray - Chest | Office | 306 | 252 | $29.17 | $8,927 |
| 94729 Pulmonary Function Testing | Office | 284 | 278 | $48.13 | $14K |
| 94727 Pulmonary Function Testing | Office | 271 | 266 | $38.06 | $10K |
| 99232 Hospital E&M - Subsequent | Facility | 247 | 115 | $65.04 | $16K |
| 99205 Office E&M - New | Office | 184 | 184 | $175.78 | $32K |
| 99223 Hospital E&M - Initial | Facility | 167 | 147 | $142.21 | $24K |
| 94060 Pulmonary Function Testing | Office | 115 | 114 | $33.67 | $3,872 |
| 99215 Office E&M - Established | Office | 114 | 113 | $154.31 | $18K |
| 94618 Pulmonary Function Testing | Office | 89 | 81 | $28.89 | $2,572 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 58 | 57 | $13.58 | $787 |
| 99496 Chronic, Principal, and Transitional Care Management | Office | 48 | 42 | $237.70 | $11K |
By year: 2022 $363K for 4,751 services; 2023 $364K for 4,929 services; 2024 $350K for 4,616 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82803 Clinical Chemistry | 14 | 14 | $25.55 | $358 |
| 36600 General Laboratory | 13 | 13 | $25.11 | $326 |
Medicare prescription drug claims, 2024
In 2024, the drug Joseph A Ball prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 738 prescriptions and refills. In total Joseph A Ball wrote 4,962 Medicare prescriptions that cost $3.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 738 | 1,048 | 165 | $655K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 440 | 625 | 187 | $14K |
| Prednisone Generic | 355 | 464 | 160 | $1,739 |
| Azelastine Hcl Generic | 351 | 628 | 158 | $15K |
| Breo Ellipta Fluticasone/Vilanterol | 255 | 437 | 72 | $167K |
| Montelukast Sodium Generic | 197 | 533 | 61 | $3,556 |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 180 | 327 | 48 | $144K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 149 | 229 | 46 | $21K |
| Spiriva Respimat Tiotropium Bromide | 146 | 248 | 49 | $125K |
| Symbicort Budesonide/Formoterol Fumarate | 131 | 232 | 46 | $51K |
| Azithromycin Generic | 130 | 158 | 67 | $2,397 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 128 | 166 | 39 | $102K |
| Advair Hfa Fluticasone Propion/Salmeterol | 101 | 123 | 18 | $43K |
| Ipratropium Bromide Generic | 98 | 155 | 35 | $3,478 |
| Incruse Ellipta Umeclidinium Bromide | 96 | 154 | 26 | $51K |
Brand drugs: 2,683 claims; generic drugs: - claims; opioid claims: 16.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joseph A Ball $4,556 ($4,556 in general payments such as food, travel and fees) from 24 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $852.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 28 | $852 |
| GlaxoSmithKline, LLC. GSK | 29 | $709 |
| Regeneron Healthcare Solutions, Inc. REGN | 10 | $350 |
| Genzyme Corporation SNY | 13 | $333 |
| Grifols USA, LLC | 11 | $319 |
| Amgen Inc. AMGN | 14 | $300 |
| Actelion Pharmaceuticals US, Inc. JNJ | 8 | $284 |
| ANI Pharmaceuticals, Inc. ANIP | 8 | $222 |
| United Therapeutics Corporation UTHR | 10 | $207 |
| Insmed, Inc. INSM | 9 | $180 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.